The success of pharmacological treatments in primary liver cancers is limited by the marked efficacy of mechanisms of chemoresistance already present in hepatocytes. The role of the nuclear receptor FXR is unclear. Although, in non-treated liver tumors, its expression is reduced, the refractoriness to anticancer drugs is high. Moreover, the treatment with cisplatin up-regulates FXR. The aim of this study was to investigate whether FXR is involved in stimulating chemoprotection/chemoresistance in healthy and tumor liver cells. In human hepatocytes, the activation of FXR with the agonist GW4064 resulted in a significant protection against cisplatin-induced toxicity. In human hepatoma Alexander cells, with negligible endogenous expression of FXR, GW4064 also protected against cisplatin-induced toxicity, but only if they were previously transfected with FXR/RXR. Investigation of 109 genes potentially involved in chemoresistance revealed that only ABCB4, TCEA2, CCL14, CCL15 and KRT13 were up-regulated by FXR activation both in human hepatocytes and FXR/ RXR-expressing hepatoma cells. In both models, cisplatin, even in the absence of FXR agonists, such as bile acids and GW4064, was able to up-regulate FXR targets genes, which was due to FXR-mediated transactivation of response elements in the promoter region. FXR-dependent chemoprotection was also efficient against other DNA-damaging compounds, such as doxorubicin, mitomycin C and potassium dichromate, but not against non-genotoxic drugs, such as colchicine, paclitaxel, acetaminophen, artesunate and sorafenib. In conclusion, ligand-dependent and independent activation of FXR stimulates mechanisms able to enhance the chemoprotection of hepatocytes against genotoxic compounds and to reduce the response of liver tumor cells to certain pharmacological treatments.
Introduction
Hepatocellular carcinoma (HCC) is the third cause of cancerrelated death worldwide. Surgery is the curative therapy of choice, but the resection of these tumors is not always possible. The use of pharmacological approaches is limited because, owing to the marked drug refractoriness of these tumors, the response to available adjuvant chemotherapy is very poor. This characteristic depends in part on the expression of the genes involved in a variety of mechanisms of chemoresistance (MOC), which are also involved in the chemoprotection of normal liver tissue. These include a reduction in drug/toxin uptake (MOC-1a), an enhanced drug/toxin export (MOC-1b), a reduction in metabolic pro-drug/toxin activation or an increase in drug/toxin inactivation (MOC-2), changes in molecular targets (MOC-3), enhanced DNA repair (MOC-4), and a modification in the pro-apoptotic (MOC-5a) versus pro-survival (MOC-5b) balance [1] .
The farnesoid X receptor (FXR, gene symbol NR1H4) is a transcription factor mainly expressed in the liver, intestine, kidney, and adrenal glands. To activate the expression of its target genes, FXR heterodimerizes with the retinoid X receptor α (RXRα) and, upon activation by specific agonists, binds to FXR response elements (FXREs), mainly IR-1 (inverted repeats separated by 1 nucleotide) [2] .
FXR has traditionally been considered as a specific bile acid receptor involved in the control of bile acid homeostasis. However, a role of FXR in the control of lipid and glucose metabolism has been described [3] , and more recently, FXR has also been implicated in the prevention of hepatic and intestinal carcinogenesis [4, 5] , liver regeneration [6] , the barrier function of the intestine [7] , attenuation of the adverse effects of cholestasis [8] and the prevention of gallstone formation [9] . To carry out some of these functions, FXR regulates the expression of genes involved in MOC, such as phase I oxidation enzymes (CYP3A4) [10] , phase II conjugation enzymes (UGT2B4 and SULT2A1) [11, 12] , and phase III transporters (BSEP and MDR3) [13, 14] . This implies a potential role of FXR in the hepatic handling of potentially toxic xenobiotics, such as acetaminophen [15] . Moreover, we have recently described a role for FXR in chemoresistance to cisplatin in colon cancer cells [16] .
Nevertheless, the role of FXR in the control of the genes involved in MOC remains unclear. Although, in non-treated liver tumors, the FXR expression is reduced, the refractoriness to antitumor drugs is high [17] . Moreover, some of them, such as cisplatin, are able to induce FXR expression in tumor cells [17] . Therefore, the aim of this study was to investigate whether FXR is involved in the activation of chemoprotection in healthy hepatocytes and liver cancer cells.
Materials and methods

Chemicals
Acetaminophen, cisplatin, colchicine, doxorubicin, mitomycin C, paclitaxel and potassium dichromate were obtained from Sigma-Aldrich (Madrid, Spain). GW4064 was obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Sorafenib tosylate was obtained through the Pharmacy Department, University Hospital (Salamanca, Spain). Artesunate was kindly provided by Dr. Thomas Effert (University of Mainz, Germany). The purity of all these compounds was ≥97%. All other chemicals were of analytical grade.
Cloning
FXRα1(−) isoform (containing exons 1 to 3 and a 12-bp deletion in exon 5) [18] and RXRα, henceforth designated simply as FXR and RXR, were cloned using Gateway technology. The coding sequences were amplified by PCR using DNA from HepG2 cells and Jeg-3 cells, respectively, and the high fidelity AccuPrime Pfx DNA polymerase and gene specific primers ( Supplementary Table 1 ) with appropriate attB adapters. The attB-flanked PCR products were recombined with the attP-containing pDONR207 vector (Invitrogen, Barcelona, Spain) to generate Entry plasmids, which were further recombined with the pcDNA6.2-V5 Destination vector (Invitrogen), to generate the Expression vectors. The pGL4. 28 [Luc2CP] vector (Promega, Madrid, Spain) was used to obtain pGL4. 28 [Luc2CP]/IR-1, containing the consensus IR-1 response element for FXR. The IR-1 (AGGTCAATGACCT) consisted of an inverted repeat of the consensus sequence AGGTCA separated by one nucleotide (A) [2] . The exact nucleotide sequence of all constructs was confirmed by gel-electrophoresis-based sequencing.
Cell culture and transfection assays
Human hepatoma Alexander cells (PLC/PRF/5, ATCC: CRL-8024), human hepatocellular carcinoma SK-Hep-1 cells (ATCC: HTB-52) and human hepatoblastoma HepG2 cells (ATCC: HB-8065) were provided by LGC Standards S.L.U., Barcelona (Spain) and cultured as recommended by the supplier. Human hepatocytes were isolated from the healthy liver tissue obtained by surgical resections of primary or secondary liver tumors after written consent of the patients (4 men, 2 women, 59 ± 5.3 years) at the Reina Sofia Hospital (Cordoba, Spain). Hepatocytes were isolated and further cultured as previously described [19] .
Transient transfection of Alexander, SK-Hep-1 and HepG2 cells was carried out with the Lipofectamine LTX and PLUS reagents (Invitrogen). Cells were transfected with an empty vector (mock) or plasmids containing FXR, RXR or both. In some cases, transfections were carried out in combination with a plasmid containing an IR-1 response element upstream of a minimal promoter (minPr) and the destabilized firefly luciferase (luc2CP) gene. After transfection (48 h), cells were incubated with 5 μM cisplatin, 1 μM GW4064, or with different concentrations of cisplatin or several toxic compounds, with or without 1 μM GW4064, over 24 h, 48 h or 72 h, depending on the parameter (cell viability, luciferase activity or mRNA levels) to be measured.
Cell viability and luciferase activity
The amount of living cells was determined using the formazan test (Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega).
Promoter activation was followed by changes in the luciferase activity, measured with the Bright-Glo Luciferase Assay System (Promega) on a LAS-4000 image reader (FujiFilm; TDI, Madrid, Spain). The intensity of the signal was expressed as arbitrary units of luminescence (light emission/10 min).
Gene expression analyses
Measurement of mRNA steady-state levels was carried out by RT-QPCR as previously reported [17, 20] . In brief, total RNA extraction from cultured cells was performed as previously described [20] . RT was carried out using the "SuperScript® VILO™ cDNA Synthesis Kit" (Invitrogen). QPCR was performed using Amplitaq Gold polymerase in an ABI Prism 7300 Sequence Detection System (Applied Biosystems, Madrid, Spain) for single reactions to determine mRNA levels by conventional RT-QPCR with SYBR® Green I detection, or using TLDAs in an ABI Prism 7900HT Sequence Detection System (Applied Biosystems) with TaqMan Mix detection. In all cases, the following thermal conditions were used: a single cycle of 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. The primer oligonucleotides for FXR and its target genes, and for the MOC genes (Supplementary Table 2 ), together with their appropriate Taqman probes to be included in the microfluidic cards, were designed and validated by us or by Applied Biosystems (TLDAs) (data not shown). Changes in the expression of the heterodimeric protein OSTα/β was following by measuring the monomer with the highest expression level in each cell type, i.e., OSTα in hepatocytes and OSTβ in Alexander cells. 18S rRNA was used as a quality-control check among samples and groups. Double normalization of the results in each sample was carried out with the values obtained for ACTB and GAPDH as previously reported [17] .
For protein detection by immunofluorescence Alexander transfected cells were fixed and permeabilized in ice-cold methanol, and nonspecific binding sites were blocked by incubation with 5% fetal calf serum. Preparations were incubated with primary antibody from Invitrogen (anti-V5 against FXR-V5 diluted 1:200) and then for 1 h with a 1:1000 dilution of Alexa Fluor-488 anti-mouse secondary antibody, and 4,6-diamidino-2-phenylindole (DAPI) to counterstain nuclei. Fluorescence staining was visualized using a Leica TCS SP2 confocal microscope.
Bile acid measurement, in silico analysis and statistical methods
Bile acid concentrations in cell cultures were determined by HPLC-MS/MS using a 6410 Triple Quad LC/MS (Agilent Technologies, Santa Clara, California, USA), as previously reported [21] .
In silico analysis for the search of putative FXR binding sites was carried out in the region of −3000 bp upstream of the start ATG codon. The sequences detected in this region by SITAR analysis were compared with target sequences of the identifiers as defined in TRANSFAC® 7.0 database.
To calculate the statistical significance of the differences between groups, the paired or unpaired t-tests were used, as appropriate.
Results
FXR activation protects against cisplatin-induced toxicity
When human hepatocytes were placed in culture, a spontaneous and progressive decrease in the expression of FXR was observed.
The abundance of FXR mRNA decreased to approximately 50% of that of human liver over the first 3-4 days in culture. Then steady state was reached and maintained for up to, at least, 12 days (Supplementary Fig. 1 ). Experiments performed within this period revealed that treatment with the FXR agonist GW4064 partly protected human hepatocytes against cisplatin-induced toxicity ( Fig. 1A) .
To further investigate this effect the human hepatoma Alexander cells, with negligible endogenous FXR steady state expression levels (0.28% ± 0.06 of human liver) ( Supplementary Fig. 2 ), were used as experimental model. These cells were transiently transfected with FXR. Prior to measuring FXR mRNA, the restriction enzyme DpnI, which cuts methylated DNA, was used to digest the remaining intracellular plasmids. A peak of FXR mRNA was observed 48 h after transfection ( Supplementary Fig. 2 ), when most FXR protein was located in the nucleus ( Supplementary Fig. 2 , inset). This time was therefore used as the starting time to expose the cells to the compounds to be tested. When the cells were transfected with the same amount of DNA but divided into two plasmids containing either FXR or RXR, the abundances of FXR mRNA and RXR mRNA 48 h after transfection were 685% ± 45 and 490% ± 35 that of human liver, respectively.
Dose-dependent studies of cisplatin-induced cell death revealed an improved survival of Alexander cells when they had been transfected with FXR + RXR and were cultured in the presence of 1 μM GW4064 ( Fig. 1B) . Thus, the cisplatin IC 50 was increased 5.8-fold under conditions of activated FXR (Fig. 2 ). Similar experiments carried out in human liver adenocarcinoma SK-Hep-1 cells also revealed a significant FXR-mediated protection against cisplatin toxicity (data not shown). Thus, the IC 50 for cisplatin in these cells was increased from 3.0 μM to 6.8 μM. In contrast, transfection with RXR alone did not modify the sensitivity of Alexander or SK-Hep-1 cells to cisplatin (Fig. 2) . Moreover, GW4064 had no effect on the sensitivity of Alexander or SK-Hep-1 cells to cisplatin when the cells were transfected with RXR either alone or with an empty vector.
Expression of genes involved in chemoresistance
To elucidate the relationship between FXR activation and enhanced chemoresistance, GW4064-induced changes in the expression levels of a set of 109 genes potentially involved in different MOC were investigated (Table 1) . Incubation with 1 μM GW4064 for 24 h resulted in a significant up-regulation of five genes involved in MOC-1b (ABCB4), MOC-4 (TCEA2), MOC-5b (CCL14, CCL15 and KRT13), both in human hepatocytes in primary culture ( Fig. 3A) and Alexander cells transfected with FXR + RXR (Fig. 3B ). No effect on Alexander cells transfected with an empty vector was found (data not shown).
Cisplatin-induced expression of FXR target genes
Since partial protection of the cells against cisplatin toxicity was also seen in FXR transfected cells even in the absence of GW4064 ( Fig. 2) , we wondered whether endogenous bile acids could be activating FXR in these cells. HPLC-MS/MS analysis revealed that, under all the experimental conditions used here, bile acid levels in Alexander cells were undetectable (data not shown).
A potential explanation would be the activation of FXR in response to the toxicity of cisplatin. To elucidate this question, human hepatocytes were treated with cisplatin, which induced no significant change in the expression of FXR (Fig. 4) . In contrast, cisplatin was able to up-regulate several FXR target genes, such as BSEP, SHP, OSTα and TCEA2 ( Fig. 4) .
To further analyze the effect of cisplatin on the FXR signaling pathway, Alexander cells were transfected with FXR + RXR and treated with cisplatin or GW4064 for 72 h, and the expression of FXR target genes was determined. In mock cells, cisplatin, but not GW4064, was already able to activate some, but not all, FXR target genes assayed (Fig. 5A ). In contrast, in FXR + RXR-transfected cells, GW4064 induced a significant effect on the expression of FXR target genes (Fig. 5B) . Surprisingly, cisplatin had a similar but weaker FXR-dependent effect on these genes (Fig. 5B ).
Cisplatin-induced activation of an IR-1 FXR-response element
The ability of cisplatin to directly or indirectly activate FXR, in the absence of bile acids or GW4064, was then investigated by determining luciferase expression driven by an IR-1 consensus element in HepG2 cells, which constitutively express FXR, and in Alexander cells transfected with FXR or FXR + RXR. In the absence of the IR-1 element, treatment with either cisplatin or GW4064 had no effect on luciferase expression ( Fig. 6A ). In contrast, in the presence of the IR-1 element both cisplatin and GW4064 (GW4064 > cisplatin) induced luciferase expression ( Fig. 6B ).
Protection against genotoxicity
Since the mechanism of action of cisplatin is based on its damaging interaction with DNA, we investigated whether, in absence of FXR, cisplatin was able to activate several genes involved in MOC-4. Indeed, p53 and p53-dependent proteins p21, GADD45 and FAS were up-regulated by cisplatin in Alexander cells (Fig. 7) . In contrast, FXR + RXR transfection plus GW4064 did not up-regulate these genes (Table 1 ). Finally, we investigated whether the protective effect of FXR activation was specific for cisplatin or it was shared with other genotoxic compounds. Transfection plus activation of FXR also protected Alexander cells against other DNA damaging agents, such as mitomycin C, doxorubicin and potassium dichromate, but not against compounds without genotoxic activity, such as colchicine, paclitaxel, acetaminophen, artesunate or sorafenib (Fig. 8 ).
Discussion
The present study revealed that activation of FXR with a typical agonist, such as GW4064, elicited partial protection against the toxic effect of cisplatin. Surprisingly, in the absence of GW4064 or other typical agonists of this nuclear receptor, such as bile acids, the expression of FXR also protected the cells against cisplatin-induced toxicity. This suggests thatdirectly or indirectlycisplatin itself, and presumably other toxic compounds, with genotoxic activity, are able to activate the FXR pathway. Indeed, only when FXR was expressed, cisplatin was able to activate luciferase expression driven by an IR-1 response element. Although not impossible, the molecular structure of cisplatin makes it unlikely that this drug would behave as a typical FXR agonist. Accordingly, it could be speculated that the mechanism of cisplatin-induced FXR activation would be different from that of its well-known ligands. Among the possibilities is FXR phosphorylation by PKCζ and PKCα, which have been shown to activate FXR in the absence of agonist [22, 23] . Moreover, DNA damage induces the activation of PKC signaling pathways, resulting in an enhanced protein kinase C activity able to phosphorylate FXR [24] . Whether other DNA-damaging agents, but not other antitumor drugs, share this mechanism of action resulting in FXR activation is not known, although DNA-damaging agents, such as doxorubicin [25] and mitomycin C [26] are known to also interact with this pathway.
An additional level of complexity was suggested by the findings that cisplatin was able to activate the expression of several FXR target genes, such as SHP and OSTβ, even in cells lacking FXR expression. In contrast, cisplatin up-regulated BSEP and TCEA2 only when FXR was expressed. The FXR-independent up-regulation of SHP has previously been described to occur through the activation of p53 triggered by DNA damage [27] . The reason for this overlap between the p53 and FXR pathways is probably that both p53 and FXR share the MLL3 methyltransferase, which forms part of a coactivator complex able to interact with multiple transcription factors [27] . Our results support the concept that p53, a master sensor of DNA damage, may be involved in an indirect activation of the transcription complex able to enhance the expression of some FXR target genes.
Regarding the mechanism by which FXR is able to induce chemoprotection, the expression of a large set of genes was analyzed. The overexpression of ABC export pumps, belonging to MOC-1b, is one of the major mechanisms accounting for the poor response of tumors to anticancer drugs. However, we only found changes in the expression of BSEP and MDR3. BSEP is a well-known target of FXR whose main function is the transport of bile acids into the canalicular lumen [28] . This pump is also able to transport some anticancer compounds, such as Table 1 Genes included in the analysis of expression levels by RT-QPCR using TLDA or single reactions. Genes are classified on the bases of their role in mechanism of chemoresistance (MOC) or the known sensitivity to FXR activation.
MOC-1a
MOC -1b  MOC-2  MOC-3  MOC-4  MOC-5a  MOC-5b  FXR Targets   Non-affected  SLC10A1  ABCA2  CES1  DHFR  ERCC1  AEG1  AKT1  CEBPB  SLC10A2  ABCA3  CES2  ESR2  DUT  BAX  BCL2  CYP3A4  SLCO2B1  ABCA6  CYP1A1  FRAP1  GADD45A  BCL2L1  BIRC1  SLCO1B1  SLCO4A1  ABCA8  CYP1A2  KDR  MLH1  BIRC2  BIRC4  SLCO1B3  SLC22A1  ABCB1  DPYD  KIT  MLH3  BIRC3  BIRC5  SLC22A2  ABCC1  GSTA1  mTOR  MSH2  CDKN1A  BIRC7  SLC22A4  ABCC2  GSTP1  PDGFRA  MSH3  DIABLO  BTG1  SLC22A5  ABCC3  TYMP  TOP1  PMS1  FAS  CASP8  SLC28A1  ABCC4  UGT1A  TOP2A  PMS2  PSMD9  CFLAR  SLC28A2  ABCC5  UMPS  TYMS  PRKDC  TP53  EGFR  SLC28A3  ABCC6  UPP1  RAD51  JUN  SLC29A1  ABCC10  UPP2  RAD51AP1  MAPK1  SLC29A2  ABCC11  TCEA1  MYC  SLC31A1 ATP7A
a Genes whose expression was significantly (p b 0.05) modified in human hepatoma Alexander cells transfected with FXR + RXR, in response to FXR activation by 1 μM GW4064.
vinblastine, but not others, such as daunorubicin or paclitaxel [29] . MDR3 is mainly expressed in the canalicular membrane of the hepatocytes, where it plays a role as phospholipid translocase [30] , but its relevance in chemoresistance is poorly understood. MDR3 is overexpressed in K562 cells resistant to doxorubicin [31] , one of the compounds whose efficacy was found to be reduced when FXR was expressed and activated. MRP2 is particularly important in the chemoresistance to cisplatin [1] . Thus, MRP2 expression levels have been correlated with the sensitivity of several cell lines to cisplatin [32] . We have previously described that cisplatin treatment is able to induce MRP2 expression in colon cancer cells [16] . Furthermore, we have reported that FXR-dependent overexpression of BCRP may also be involved in the chemoresistance of colon cancer to cisplatin [16] . However, in liver cells, no significant changes in the expression of MRP2 or BCRP in response to FXR activation have been found. Although MOC-2 and MOC-3 include FXR target genes, such as CEBPB and CYP3A4, no changes in the expression of these genes in response to FXR activation was found. In contrast, interesting results regarding MOC-4 were obtained. The expression of TCEA2, recently reported as an FXR target gene [33] , was induced after the activation of FXR. The protein encoded by this gene, TFIIS, is an elongation factor involved in the transcription-coupled DNA repair mechanism and has previously been associated with chemoresistance to cisplatin [34] . The FXR-mediated up-regulation of TCEA2, but not of TCEA1 or TCEA3, found in the present study suggest that only the isoform 2 of this protein is probably involved in the enhanced chemoresistance to agents with known ability to induce DNA damage, such as doxorubicin, mitomycin C, cisplatin and potassium dichromate [35] .
Changes in the expression of genes belonging to MOC-5 could account for the reduced sensitivity to mitomycin C, whose mechanism of action includes the up-regulation of caspase-8, which leads to apoptosis [36] . Since KRT13 has anti-apoptotic properties [37] , the up-regulation of this protein may result in enhanced protection against the toxicity of mitomycin C, and other pro-apoptotic drugs used in this study. Although the mechanism of action of artesunate involves the up-regulation of a large number of pro-apoptotic genes and the down-regulation of others [38] , we have found no changes in the expression of these genes. Thus, the absence of FXR-induced chemoresistance to artesunate was probably related to the lack of effect on the proapoptotic/survival balance in our experimental setting. Regarding the FXR-dependent enhanced expression of CCL14 and CCL15, although chemokines are involved in angiogenesis and cell proliferation, migration, invasion and metastasis [39] their role in the chemoprotective response to FXR remains unclear.
Data obtained by other groups support the hypothesis that FXR can be involved in the regulation of some of the 5 genes (ABCB4, TCEA2, CCL14, CCL15 and KRT13) whose expression we have found here to be sensitive to FXR activation. Thus, Huang et al. have shown that the FXR/RXR heterodimer binds specifically to the IR-1 element in the human ABCB4 promoter [13] . Moreover, Cuesta et al., have recently shown that the TCEA2 gene is also regulated by FXR [33] . The fact that FXR bound to a conserved regulatory element in the proximal human KRT13 promoter has also been described [37] . Moreover, in silico analysis in the search of potential sites for FXR-mediated regulation in the promoter region of these 5 genes has revealed several putative binding sites for FXR in all of them (Table 2) , whose actual role in chemoresistance remain to be elucidated.
Conclusions
In conclusion, these results indicate that the ligand-dependent and independent activation of FXR and/or its signaling pathway is involved in the chemoprotective response of liver cells. This is due in part to changes in the expression of several genes (ABCB4, TCEA2, CCL14, CCL15 and KRT13) accounting for different MOC, mainly these involved in drug efflux (MOC-1b), DNA repair (MOC-4) and cell survival (MOC-5b). Moreover, this characteristic is shared by healthy and tumor cells, and hence may play an important role in enhancing the chemoprotection of healthy hepatocytes against genotoxic compounds and reducing the response of liver tumor cells to certain pharmacological treatments.
Supplementary data to this article can be found online at http:// dx.doi.org/10.1016/j.bbamcr.2013.05.006. 
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